BCR and chronic myelogenous leukemia, BCR-ABL1 positive: In order to test whether inhibition of ILK may have a role for the treatment of BCR-ABL1T315I+ CML, we treated mice with BCR-ABL1T315I+ CML with vehicle, ponatinib, the ILK inhibitor Cpd22 [43], or the combination of Cpd22 and ponatinib.